Co-Authors
This is a "connection" page, showing publications co-authored by Haiming Wei and Binqing Fu.
Connection Strength
2.367
-
Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020 04 14; 18(1):164.
Score: 0.877
-
IL-6 modulation for COVID-19: the right patients at the right time? J Immunother Cancer. 2021 04; 9(4).
Score: 0.234
-
Pyroptotic macrophages stimulate the SARS-CoV-2-associated cytokine storm. Cell Mol Immunol. 2021 05; 18(5):1305-1307.
Score: 0.234
-
Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status. J Autoimmun. 2021 03; 118:102596.
Score: 0.231
-
Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients. Proc Natl Acad Sci U S A. 2020 12 08; 117(49):30898-30899.
Score: 0.228
-
Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention. Proc Natl Acad Sci U S A. 2020 12 01; 117(48):30027-30028.
Score: 0.228
-
Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 05 19; 117(20):10970-10975.
Score: 0.220
-
Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med. 2021 Jun; 15(3):486-494.
Score: 0.058
-
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat Commun. 2020 08 06; 11(1):3924.
Score: 0.056